menu
    • menu

    Company profile for Arvinas

    NEW Drugs in Dev: 7
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of canc...
    Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ArvinasUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5 Science Park 395 Winchester Ave. New Haven, CT 06511
    Telephone
    Telephone
    +1.203.535.1456
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.arvinas.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/arvinas/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arvinas ARV-102 Shows >50% LRRK2 Drop In Parkinson’s CSF
    Arvinas ARV-102 Shows >50% LRRK2 Drop In Parkinson’s CSF

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258013/0/en/Arvinas-Announces-Positive-Phase-1-Data-for-ARV-102-Showing-Greater-Than-50-LRRK2-Degradation-in-the-CSF-of-Patients-with-Parkinson-s-Disease-Treated-for-28-Days.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Arvinas Presents Phase 1 ARV-102 Data at 2026 AD/PD Conference
    Arvinas Presents Phase 1 ARV-102 Data at 2026 AD/PD Conference

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3253623/0/en/Arvinas-to-Present-Phase-1-Data-for-ARV-102-a-PROTAC-LRRK2-Degrader-in-Oral-Session-at-the-2026-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-and-Related-Neurolo.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Arvinas Reports 2025 Financial Results And Corporate Update
    Arvinas Reports 2025 Financial Results And Corporate Update

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243370/0/en/Arvinas-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Arvinas To Participate In Upcoming Investor Conferences
    Arvinas To Participate In Upcoming Investor Conferences

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242463/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Arvinas To Release Q4 And Full Year 2025 Financial Results
    Arvinas To Release Q4 And Full Year 2025 Financial Results

    17 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/17/3239071/0/en/Arvinas-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-24-2026.html

    GLOBENEWSWIRE
    17 Feb 2026
    Share Share
    Arvinas Names Randy Teel, Ph.D., as President, CEO, & Director
    Arvinas Names Randy Teel, Ph.D., as President, CEO, & Director

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237054/0/en/Arvinas-Announces-Appointment-of-Randy-Teel-Ph-D-as-President-Chief-Executive-Officer-and-Director.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search